LCTX Long Call Strategy

LCTX (Lineage Cell Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on AMEX.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019.

LCTX (Lineage Cell Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $318.8M, a beta of 1.60 versus the broader market, a 52-week range of 0.45-2.09, average daily share volume of 1.2M, a public-listing history dating back to 1992, approximately 70 full-time employees. These structural characteristics shape how LCTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.60 indicates LCTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on LCTX?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current LCTX snapshot

As of May 15, 2026, spot at $1.27, ATM IV 174.30%, IV rank 32.26%, expected move 49.97%. The long call on LCTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on LCTX specifically: LCTX IV at 174.30% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 49.97% (roughly $0.63 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LCTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on LCTX should anchor to the underlying notional of $1.27 per share and to the trader's directional view on LCTX stock.

LCTX long call setup

The LCTX long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LCTX near $1.27, the first option leg uses a $1.27 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LCTX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LCTX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$1.27N/A

LCTX long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

LCTX long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on LCTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on LCTX

Long calls on LCTX express a bullish thesis with defined risk; traders use them ahead of LCTX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

LCTX thesis for this long call

The market-implied 1-standard-deviation range for LCTX extends from approximately $0.64 on the downside to $1.90 on the upside. A LCTX long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current LCTX IV rank near 32.26% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on LCTX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, LCTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LCTX-specific events.

LCTX long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LCTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LCTX alongside the broader basket even when LCTX-specific fundamentals are unchanged. Long-premium structures like a long call on LCTX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current LCTX chain quotes before placing a trade.

Frequently asked questions

What is a long call on LCTX?
A long call on LCTX is the long call strategy applied to LCTX (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With LCTX stock trading near $1.27, the strikes shown on this page are snapped to the nearest listed LCTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are LCTX long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the LCTX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 174.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a LCTX long call?
The breakeven for the LCTX long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LCTX market-implied 1-standard-deviation expected move is approximately 49.97%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on LCTX?
Long calls on LCTX express a bullish thesis with defined risk; traders use them ahead of LCTX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current LCTX implied volatility affect this long call?
LCTX ATM IV is at 174.30% with IV rank near 32.26%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related LCTX analysis